Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iX BiopharmaSGX:42C +0.92%36 Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus rates SGX:42C with a GF Score™ of 36/100 and a GF Value™ of S$0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 448 Drug Manufacturers companies, iX Biopharma ranks worse than 223214.06% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. iX Biopharma's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.00.
The historical rank and industry rank for iX Biopharma's Dividend Payout Ratio or its related term are showing as below:
SGX:42C's Dividend Payout Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.38 * Ranked among companies with meaningful Dividend Payout Ratio only.
iX Biopharma (SGX:42C) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
iX Biopharma Dividend Payout Ratio Related Terms
iX Biopharma Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for iX Biopharma's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:42C vs ZTS, UTHR, VTRS: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iX Biopharma Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where iX Biopharma's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
iX Biopharma's Dividend Payout Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iX Biopharma (SGX:42C) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on iX Biopharma and its competitors. According to the industry distribution chart, iX Biopharma ranks #999999 out of 448 companies in the Drug Manufacturers industry.
Is iX Biopharma's Dividend Payout Ratio too high?
iX Biopharma's current Dividend Payout Ratio is 0.00. Based on the distribution chart, iX Biopharma ranks #999999 out of 448 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, iX Biopharma has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, iX Biopharma ranks #999999 out of 448 companies for Dividend Payout Ratio. This places iX Biopharma in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 448 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on iX Biopharma and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iX Biopharma's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
Based on GuruFocus' analysis, iX Biopharma (SGX:42C) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.03, compared to a current price of S$0.55 — trading 1733.3% above its estimated fair value. The current Dividend Payout Ratio is 0.00. iX Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iX Biopharma (SGX:42C) Overvalued in 2026?
Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued.
The current stock price of S$0.55 is trading 1733.3% above its estimated GF Value™ of S$0.03.
GuruFocus considers iX Biopharma to be Significantly Overvalued.
Key valuation signals for SGX:42C:
Dividend Payout Ratio: 0.00
GF Value™: S$0.03 vs. price of S$0.55 (1733.3% above fair value)
No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score
Get the complete analysis for SGX:42C
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:42C has been successfully added to your 
